$8.13
-0.41[-4.80%]
At close: Apr 16
$8.13
0[0.00%]
After Hours: 4:00PM EDT
RAPT Therapeutics
(NASDAQ:RAPT)RAPT Therapeutics Stock (NASDAQ:RAPT), Analyst Ratings, Price Targets, Predictions
RAPT Therapeutics Inc has a consensus price target of $29.17, established from looking at the 45 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., JP Morgan, and UBS on April 10, 2024, March 27, 2024, and February 22, 2024. With an average price target of $7.67 between HC Wainwright & Co., JP Morgan, and UBS, there's an implied -5.70% downside for RAPT Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
JP Morgan
UBS
Barclays
Leerink Partners
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for RAPT Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/10/2024 | RAPT | Buy Now | RAPT Therapeutics | $8.13 | — | HC Wainwright & Co. | Raghuram Selvaraju | — | Reiterates | → Neutral | Get Alert |
| 03/27/2024 | RAPT | Buy Now | RAPT Therapeutics | $8.13 | 59.9% | JP Morgan | Anupam Rama | $15 → $13 | Maintains | Neutral | Get Alert |
| 02/22/2024 | RAPT | Buy Now | RAPT Therapeutics | $8.13 | 23% | UBS | Eliana Merle | $61 → $10 | Downgrade | Buy → Neutral | Get Alert |
| 02/21/2024 | RAPT | Buy Now | RAPT Therapeutics | $8.13 | 59.9% | Barclays | Leon Wang | $35 → $13 | Maintains | Overweight | Get Alert |
| 02/21/2024 | RAPT | Buy Now | RAPT Therapeutics | $8.13 | 23% | Leerink Partners | Thomas Smith | → $10 | Downgrade | Outperform → Market Perform | Get Alert |
| 02/21/2024 | RAPT | Buy Now | RAPT Therapeutics | $8.13 | — | HC Wainwright & Co. | Raghuram Selvaraju | — | Downgrade | Buy → Neutral | Get Alert |
| 02/21/2024 | RAPT | Buy Now | RAPT Therapeutics | $8.13 | 84.5% | JP Morgan | Anupam Rama | $35 → $15 | Downgrade | Overweight → Neutral | Get Alert |
| 02/20/2024 | RAPT | Buy Now | RAPT Therapeutics | $8.13 | — | Cantor Fitzgerald | Prakhar Agrawal | — | Downgrade | Overweight → Neutral | Get Alert |
| 02/16/2024 | RAPT | Buy Now | RAPT Therapeutics | $8.13 | — | Evercore ISI Group | Umer Raffat | — | Initiates | → Outperform | Get Alert |
| 02/15/2024 | RAPT | Buy Now | RAPT Therapeutics | $8.13 | 379.7% | Wolfe Research | Andy Chen | → $39 | Initiates | → Outperform | Get Alert |
| 11/30/2023 | RAPT | Buy Now | RAPT Therapeutics | $8.13 | 330.5% | JP Morgan | Anupam Rama | $32 → $35 | Maintains | Overweight | Get Alert |
| 11/15/2023 | RAPT | Buy Now | RAPT Therapeutics | $8.13 | 404.31% | HC Wainwright & Co. | Raghuram Selvaraju | → $41 | Reiterates | Buy → Buy | Get Alert |
| 09/14/2023 | RAPT | Buy Now | RAPT Therapeutics | $8.13 | 318.2% | Berenberg | Andy Chen | → $34 | Initiates | → Buy | Get Alert |
| 08/16/2023 | RAPT | Buy Now | RAPT Therapeutics | $8.13 | 293.6% | JP Morgan | Anupam Rama | $39 → $32 | Maintains | Overweight | Get Alert |
| 08/14/2023 | RAPT | Buy Now | RAPT Therapeutics | $8.13 | 281.3% | Piper Sandler | Edward Tenthoff | $28 → $31 | Maintains | Overweight | Get Alert |
| 08/14/2023 | RAPT | Buy Now | RAPT Therapeutics | $8.13 | 404.31% | HC Wainwright & Co. | Raghuram Selvaraju | → $41 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | RAPT | Buy Now | RAPT Therapeutics | $8.13 | 392% | Stifel | Alex Thompson | → $40 | Initiates | → Buy | Get Alert |
| 06/15/2023 | RAPT | Buy Now | RAPT Therapeutics | $8.13 | 330.5% | Barclays | Leon Wang | → $35 | Initiates | → Overweight | Get Alert |
| 06/05/2023 | RAPT | Buy Now | RAPT Therapeutics | $8.13 | 404.31% | HC Wainwright & Co. | Raghuram Selvaraju | → $41 | Reiterates | Buy → Buy | Get Alert |
FAQ
What is the target price for RAPT Therapeutics (RAPT)?
The latest price target for RAPT Therapeutics (NASDAQ: RAPT) was reported by HC Wainwright & Co. on April 10, 2024. The analyst firm set a price target for $0.00 expecting RAPT to fall to within 12 months (a possible -100.00% downside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for RAPT Therapeutics (RAPT)?
The latest analyst rating for RAPT Therapeutics (NASDAQ: RAPT) was provided by HC Wainwright & Co., and RAPT Therapeutics reiterated their neutral rating.
When was the last upgrade for RAPT Therapeutics (RAPT)?
There is no last upgrade for RAPT Therapeutics.
When was the last downgrade for RAPT Therapeutics (RAPT)?
The last downgrade for RAPT Therapeutics Inc happened on February 22, 2024 when UBS changed their price target from $61 to $10 for RAPT Therapeutics Inc.
When is the next analyst rating going to be posted or updated for RAPT Therapeutics (RAPT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of RAPT Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for RAPT Therapeutics was filed on April 10, 2024 so you should expect the next rating to be made available sometime around April 10, 2025.
Is the Analyst Rating RAPT Therapeutics (RAPT) correct?
While ratings are subjective and will change, the latest RAPT Therapeutics (RAPT) rating was a reiterated with a price target of $0.00 to $0.00. The current price RAPT Therapeutics (RAPT) is trading at is $8.13, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.